Breast cancer survivors are not getting the recommended level of screening, post-surgery, according to a study in JNCCN – Journal of the National Comprehensive Cancer Network.
In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).
